Literature DB >> 9925528

Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.

J R Aeschlimann1, L D Dresser, G W Kaatz, M J Rybak.   

Abstract

NorA is a membrane-associated multidrug efflux protein that can decrease susceptibility to fluoroquinolones in Staphylococcus aureus. To determine the effect of NorA inhibition on the pharmacodynamics of fluoroquinolones, we evaluated the activities of levofloxacin, ciprofloxacin, and norfloxacin with and without various NorA inhibitors against three genetically related strains of S. aureus (SA 1199, the wild-type; SA 1199B, a NorA hyperproducer with a grlA mutation; and SA 1199-3, a strain that inducibly hyperproduces NorA) using susceptibility testing, time-kill curves, and postantibiotic effect (PAE) methods. Levofloxacin had the most potent activity against all three strains and was minimally affected by addition of NorA inhibitors. In contrast, reserpine, omeprazole, and lansoprazole produced 4-fold decreases in ciprofloxacin and norfloxacin MICs and MBCs for SA 1199 and 4- to 16-fold decreases for both SA 1199B and SA 1199-3. In time-kill experiments reserpine, omeprazole, or lansoprazole increased levofloxacin activity against SA 1199-3 alone by 2 log10 CFU/ml and increased norfloxacin and ciprofloxacin activities against all three strains by 0.5 to 4 log10 CFU/ml. Reserpine and omeprazole increased norfloxacin PAEs on SA 1199, SA 1199B, and SA 1199-3 from 0.9, 0.6, and 0.2 h to 2.5 to 4.5, 1.1 to 1.3, and 0.4 to 1.1 h, respectively; similar effects were observed with ciprofloxacin. Reserpine and omeprazole increased the levofloxacin PAE only on SA 1199B (from 1.6 to 5.0 and 3.1 h, respectively). In conclusion, the NorA inhibitors dramatically improved the activities of the more hydrophilic fluoroquinolones (norfloxacin and ciprofloxacin). These compounds may restore the activities of these fluoroquinolones against resistant strains of S. aureus or may potentially enhance their activities against sensitive strains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925528      PMCID: PMC89073     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; T Yamaguchi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

2.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Signal of induction of recA protein in E. coli.

Authors:  B Salles; M Defais
Journal:  Mutat Res       Date:  1984-02       Impact factor: 2.433

4.  Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.

Authors:  S Yoshida; T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.

Authors:  A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 6.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.

Authors:  M N Dudley; H D Mandler; D Gilbert; J Ericson; K H Mayer; S H Zinner
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Different patterns of bacterial DNA synthesis during postantibiotic effect.

Authors:  M Gottfredsson; H Erlendsdóttir; A Gudmundsson; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

9.  Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  27 in total

Review 1.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

Review 2.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Mode of action of microbial bioactive metabolites.

Authors:  V Bethal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

4.  Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.

Authors:  Céline Vidaillac; Jean Guillon; Corinne Arpin; Isabelle Forfar-Bares; Boubakar B Ba; Jean Grellet; Stéphane Moreau; Daniel-Henri Caignard; Christian Jarry; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

5.  Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.

Authors:  Jean Pierre Brincat; Fabio Broccatelli; Stefano Sabatini; Maria Frosini; Annalisa Neri; Glenn W Kaatz; Gabriele Cruciani; Emanuele Carosati
Journal:  ACS Med Chem Lett       Date:  2012-01-23       Impact factor: 4.345

6.  Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.

Authors:  P N Markham; E Westhaus; K Klyachko; M E Johnson; A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.

Authors:  Ying Ying Chan; Yong Mei Ong; Kim Lee Chua
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

8.  Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori.

Authors:  Zhan Zhang; Zhi-Qiang Liu; Peng-Yuan Zheng; Fu-Ai Tang; Ping-Chang Yang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

9.  In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.

Authors:  Gregory T Robertson; Eric J Bonventre; Timothy B Doyle; Qun Du; Leonard Duncan; Timothy W Morris; Eric D Roche; Dalai Yan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus.

Authors:  Glenn W Kaatz; Varsha V Moudgal; Susan M Seo; Jette E Kristiansen
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.